159 related articles for article (PubMed ID: 22254159)
1. The use of Stronger Neo-Minophagen C, a glycyrrhizin-containing preparation, in robust neuroprotection in the postischemic brain.
Kim SW; Lim CM; Lee HK; Lee JK
Anat Cell Biol; 2011 Dec; 44(4):304-13. PubMed ID: 22254159
[TBL] [Abstract][Full Text] [Related]
2. Glycyrrhizic acid affords robust neuroprotection in the postischemic brain via anti-inflammatory effect by inhibiting HMGB1 phosphorylation and secretion.
Kim SW; Jin Y; Shin JH; Kim ID; Lee HK; Park S; Han PL; Lee JK
Neurobiol Dis; 2012 Apr; 46(1):147-56. PubMed ID: 22266336
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment of chronic hepatitis C with glycyrrhizin [stronger neo-minophagen C (SNMC)] for preventing liver cirrhosis and hepatocellular carcinoma.
Kumada H
Oncology; 2002; 62 Suppl 1():94-100. PubMed ID: 11868794
[TBL] [Abstract][Full Text] [Related]
4. Stronger Neo-Minophagen C, a glycyrrhizin-containing preparation, protects liver against carbon tetrachloride-induced oxidative stress in transgenic mice expressing the hepatitis C virus polyprotein.
Hidaka I; Hino K; Korenaga M; Gondo T; Nishina S; Ando M; Okuda M; Sakaida I
Liver Int; 2007 Aug; 27(6):845-53. PubMed ID: 17617128
[TBL] [Abstract][Full Text] [Related]
5. Glycyrrhizin attenuates kainic Acid-induced neuronal cell death in the mouse hippocampus.
Luo L; Jin Y; Kim ID; Lee JK
Exp Neurobiol; 2013 Jun; 22(2):107-15. PubMed ID: 23833559
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Stronger Neo-Minophagen C compared between two doses administered three times a week on patients with chronic viral hepatitis.
Miyake K; Tango T; Ota Y; Mitamura K; Yoshiba M; Kako M; Hayashi S; Ikeda Y; Hayashida N; Iwabuchi S; Sato Y; Tomi T; Funaki N; Hashimoto N; Umeda T; Miyazaki J; Tanaka K; Endo Y; Suzuki H
J Gastroenterol Hepatol; 2002 Nov; 17(11):1198-204. PubMed ID: 12453280
[TBL] [Abstract][Full Text] [Related]
7. Effects of glycyrrhizin (SNMC: Stronger Neo-Minophagen C) in hemophilia patients with HIV-1 infection.
Mori K; Sakai H; Suzuki S; Akutsu Y; Ishikawa M; Imaizumi M; Tada K; Aihara M; Sawada Y; Yokoyama M
Tohoku J Exp Med; 1990 Oct; 162(2):183-93. PubMed ID: 2129071
[TBL] [Abstract][Full Text] [Related]
8. Quick and simple method for increasing the reduced albumin fraction in human serum albumin preparations by using stronger neo-minophagen C.
Sakata M; Kawaguchi T; Taniguchi E; Abe M; Koga H; Sata M
Hepatol Res; 2011 Nov; 41(11):1120-5. PubMed ID: 22032679
[TBL] [Abstract][Full Text] [Related]
9. The long term efficacy of glycyrrhizin in chronic hepatitis C patients.
Arase Y; Ikeda K; Murashima N; Chayama K; Tsubota A; Koida I; Suzuki Y; Saitoh S; Kobayashi M; Kumada H
Cancer; 1997 Apr; 79(8):1494-500. PubMed ID: 9118029
[TBL] [Abstract][Full Text] [Related]
10. [Effect of glycyrrhizin on anti-tuberculosis drug-induced hepatitis].
Miyazawa N; Takahashi H; Yoshiike Y; Ogura T; Watanuki Y; Sato M; Kakemizu N; Yamakawa Y; U CH; Goto H; Odagiri S
Kekkaku; 2003 Jan; 78(1):15-9. PubMed ID: 12655701
[TBL] [Abstract][Full Text] [Related]
11. Randomized clinical trial with two doses (100 and 40 ml) of Stronger Neo-Minophagen C in Chinese patients with chronic hepatitis B.
Zhang L; Wang B
Hepatol Res; 2002 Nov; 24(3):220. PubMed ID: 12393023
[TBL] [Abstract][Full Text] [Related]
12. [Bronchial asthma due to Stronger Neo-Minophagen C].
Nakatsumi Y; Abe T; Nomura G; Fujimura M; Matsuda T
Nihon Kokyuki Gakkai Zasshi; 1998 Jul; 36(7):644-6. PubMed ID: 9805919
[TBL] [Abstract][Full Text] [Related]
13. Intranasal Delivery of RGD Motif-Containing Osteopontin Icosamer Confers Neuroprotection in the Postischemic Brain via αvβ3 Integrin Binding.
Jin YC; Lee H; Kim SW; Kim ID; Lee HK; Lee Y; Han PL; Lee JK
Mol Neurobiol; 2016 Oct; 53(8):5652-63. PubMed ID: 26482372
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms underlying the activation of cytotoxic function mediated by hepatic lymphocytes following the administration of glycyrrhizin.
Miyaji C; Miyakawa R; Watanabe H; Kawamura H; Abo T
Int Immunopharmacol; 2002 Jul; 2(8):1079-86. PubMed ID: 12349945
[TBL] [Abstract][Full Text] [Related]
15. Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect.
Lim CM; Kim SW; Park JY; Kim C; Yoon SH; Lee JK
J Neurosci Res; 2009 Mar; 87(4):1037-45. PubMed ID: 18855941
[TBL] [Abstract][Full Text] [Related]
16. Combination treatment with ethyl pyruvate and aspirin enhances neuroprotection in the postischemic brain.
Kim SW; Jeong JY; Kim HJ; Seo JS; Han PL; Yoon SH; Lee JK
Neurotox Res; 2010 Jan; 17(1):39-49. PubMed ID: 19636661
[TBL] [Abstract][Full Text] [Related]
17. A glycyrrhizin-containing preparation reduces hepatic steatosis induced by hepatitis C virus protein and iron in mice.
Korenaga M; Hidaka I; Nishina S; Sakai A; Shinozaki A; Gondo T; Furutani T; Kawano H; Sakaida I; Hino K
Liver Int; 2011 Apr; 31(4):552-60. PubMed ID: 21382166
[TBL] [Abstract][Full Text] [Related]
18. Anti-inflammatory effects of OBA-09, a salicylic acid/pyruvate ester, in the postischemic brain.
Lee HK; Kim SW; Jin Y; Kim ID; Park JY; Yoon SH; Lee JK
Brain Res; 2013 Aug; 1528():68-79. PubMed ID: 23850644
[TBL] [Abstract][Full Text] [Related]
19. [Protective effect of SNMC on mice with fulminant liver failure].
Chen LY; Yang BS; Ma YJ; Bi MR; Gao F
Zhonghua Gan Zang Bing Za Zhi; 2005 Mar; 13(3):209-12. PubMed ID: 15760558
[TBL] [Abstract][Full Text] [Related]
20. Protective effect and mechanism of stronger neo-minophagen C against fulminant hepatic failure.
Yang BS; Ma YJ; Wang Y; Chen LY; Bi MR; Yan BZ; Bai L; Zhou H; Wang FX
World J Gastroenterol; 2007 Jan; 13(3):462-6. PubMed ID: 17230620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
